Concentration by Flotation of a Complex Galena - Sphalerite - Chalcopyrite Ore from the Nine Mile District Near Missoula, Montana

At the present time ore bodies being mined are becoming more and more complex in mineral association, thus presenting a more difficult problem in their concentration. Lead-zinc sulphide ores are among the more common ores which present such difficulties.

Vermiculite, Occurence, Character, and Concentration of Mineral from the Pony District, Madison County, Montana

The purpose of this paper is to investigate the occurrence and character of the vermiculite deposits approximately four miles northwest of Pony; Madison County, Montana. The deposits are situated in rolling foothills at the northern end of the Tobacco Root Mountains.

Flotation Concentration of a Montana Lead-Zinc-Silver-Ore

The Mike Horse mine, in the Huddelston mining district, is fifty-two miles northwest of Helena, Montana. The mine was discovered in 1898 by Joseph Heitmiller. There was only minor production from the date of discovery until 1915; the main drawback being lack of good road.

Concentration of Manganese Dioxide from Philipsburg, Montana

Imports of manganese ore probably supply a major proportion of the needs of the United States. Domestic production is reported to be higher than pre-war levels, but does not equal that of the peak production year of 1943. In 1946, the Anaconda Copper Mining Company ac­counted for 90 percent of the total shipments of mangan­ese nodules, and this company is the largest producer of domestic metallurgical ore in the United States.

H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients

H-ficolin (Hakata antigen, ficolin-3) activates the lectin pathway of complement similar to mannose-binding lectin. However, its impact on susceptibility to infection is currently unknown. This study investigated whether the serum concentration of H-ficolin at diagnosis is associated with fever and neutropenia (FN) in paediatric cancer patients. H-ficolin was measured by time-resolved immunofluorometric assay in serum taken at cancer diagnosis from 94 children treated with chemotherapy. The association of FN episodes with H-ficolin serum concentration was analysed by multivariate Poisson regression. Median concentration of H-ficolin in serum was 26 mg/l (range 6-83). Seven (7%) children had low H-ficolin (< 14 mg/l). During a cumulative chemotherapy exposure time of 82 years, 177 FN episodes were recorded, 35 (20%) of them with bacteraemia. Children with low H-ficolin had a significantly increased risk to develop FN [relative risk (RR) 2.24; 95% confidence interval (CI) 1.38-3.65; P = 0.004], resulting in prolonged duration of hospitalization and of intravenous anti-microbial therapy. Bacteraemia occurred more frequently in children with low H-ficolin (RR 2.82; CI 1.02-7.76; P = 0.045). In conclusion, low concentration of H-ficolin was associated with an increased risk of FN, particularly FN with bacteraemia, in children treated with chemotherapy for cancer. Low H-ficolin thus represents a novel risk factor for chemotherapy-related infections.

Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients

Hyperkalemia is a common life-threatening problem in hemodialysis patients. Because glycyrrhetinic acid (GA) inhibits the enzyme 11beta-hydroxy-steroid dehydrogenase II and thereby increases cortisol availability to the colonic mineralocorticoid receptor, it has the potential to lower serum potassium concentrations. To test this, 10 patients in a 6 month prospective, double-blind, placebo-controlled crossover study were given cookies or bread rolls supplemented with glycyrrhetinic acid or placebo. Twenty-four-hour blood pressure measurements were performed at baseline and week 6 and 12 of each treatment period. The ratio of plasma cortisol/cortisone was significantly increased in all patients on GA as compared to baseline or placebo, indicating appropriate enzyme inhibition. Nine of the 10 patients had a persistent decrease in predialysis serum potassium concentration. On GA, mean predialysis serum potassium was significantly lower than at baseline or on placebo. On placebo, serum potassium was significantly elevated above the upper limit of normal in 76% compared to 30% of measurements during GA treatment. Furthermore, on this treatment the frequency of severe hyperkalemia significantly decreased from 9% to 0.6%. No differences were found in parameters reflecting sodium retention. Although these studies show that prolonged GA supplementation persistently lowers serum potassium in dialysis patients, a long-term toxicity study will be mandatory before we recommend the routine use of this treatment.